Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 9
Submit an article Journal homepage
520
Views
68
CrossRef citations to date
0
Altmetric
Review

Vaccines and vaccination against tick-borne encephalitis

Herwig Kollaritsch Department of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria; Department of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria
,
Maria Paulke-Korinek Department of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria; Department of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria. [email protected]
,
Heidemarie Holzmann Department of Virology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria; Department of Virology, Medical University of Vienna, Kinderspitalgasse 15, Vienna, Austria
,
Joachim Hombach Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland; Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland
,
Bjarne Bjorvatn Centre for International Health, University of Bergen, P.b. 7804, 5020 Bergen, Norway; Centre for International Health, University of Bergen, P.b. 7804, 5020 Bergen, Norway
&
Alan Barrett Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0436, USA; Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0436, USA
Pages 1103-1119 | Published online: 09 Jan 2014

References

  • Holzmann H, Aberle SW, Stiasny K et al. Tick-borne encephalitis from eating goat cheese in a mountain region of Austria. Emerging Infect. Dis. 15(10), 1671–1673 (2009).
  • World Health Organization. Vaccines against tick-borne encephalitis: WHO position paper. WER 24(86), 241–256 (2011).
  • Suess J. Tick borne encephalitis 2010: epidemiology, risk areas and virus strains in Europe and Asia – an overview. Ticks Tick. Borne. Dis. 2(1), 2–15 (2011).
  • Barrett P, Plotkin S, Ehrlich H. Tick borne encephalitis virus vaccines. In: Vaccines. Plotkin S, Orenstein W, Offit P (Eds). Saunders Elsevier, PA, USA, 841–856 (2008).
  • Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res. 57(1–2), 129–146 (2003).
  • Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T. Tick-borne encephalitis virus – a review of an emerging zoonosis. J. Gen. Virol. 90(Pt 8), 1781–1794 (2009).
  • Waldenstrom J, Lundkvist A, Falk KI et al. Migrating birds and tickborne encephalitis virus. Emerg. Infect. Dis. 13(8), 1215–1218 (2007).
  • Kriz B, Benes C, Danielová V, Daniel M. Socio–economic conditions and other anthropogenic factors influencing tick-borne encephalitis incidence in the Czech Republic. Int. J. Med. Microbiol. 293(Suppl. 37), 63–68 (2004).
  • Sumilo D, Asokliene L, Avsic-Zupanc T et al. Behavioural responses to perceived risk of tick-borne encephalitis: vaccination and avoidance in the Baltics and Slovenia. Vaccine 26(21), 2580–2588 (2008).
  • Randolph SE. To what extent has climate change contributed to the recent epidemiology of tick-borne diseases? Vet. Parasitol. 167(2–4), 92–94 (2010).
  • Randolph SE; EDEN-TBD sub-project team. Human activities predominate in determining changing incidence of tick-borne encephalitis in Europe. Euro. Surveill. 15(27), 24–31 (2010).
  • Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 122(Pt 11), 2067–2078 (1999).
  • Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25(43), 7559–7567 (2007).
  • Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst. Rev. (1), CD000977 (2009).
  • Heinz F, Stiasny K. Flaviviren. In: Medizinische Virologie. Doerr H, Gerlich W (Eds). Georg Thieme, Stuttgart, Germany, 380–386 (2010).
  • Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J. Gen. Virol. 80 (Pt 1), 179–185 (1999).
  • Grard G, Moureau G, Charrel RN et al. Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology 361(1), 80–92 (2007).
  • Heinz FX. Epitope mapping of flavivirus glycoproteins. Adv. Virus Res. 31, 103–168 (1986).
  • Danielová V, Holubová J, Pejcoch M, Daniel M. Potential significance of transovarial transmission in the circulation of tick-borne encephalitis virus. Folia Parasitol. 49(4), 323–325 (2002).
  • Kaiser R. Tick-borne encephalitis. Infect. Dis. Clin. North Am. 22(3), 561–575 (2008).
  • Donoso Mantke O, Escadafal C, Niedrig M, Pfeffer M; Working Group For Tick-Borne Encephalitis Virus C. Tick-borne encephalitis in Europe, 2007 to 2009. Euro. Surveill. 16(39), pii: 19976 (2011).
  • Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 371(9627), 1861–1871 (2008).
  • Petri E, Gniel D, Zent O. Tick-borne encephalitis (TBE) trends in epidemiology and current and future management. Travel Med. Infect. Dis. 8(4), 233–245 (2010).
  • Suess JA. Protecting our antibiotic lifeline, Part II. Mich. Med. 102(5), 25 (2003).
  • Ko S, Kang JG, Kim SY et al. Prevalence of tick-borne encephalitis virus in ticks from southern Korea. J. Vet. Sci. 11(3), 197–203 (2010).
  • Lukan M, Bullova E, Petko B. Climate warming and tick-borne encephalitis, Slovakia. Emerging Infect. Dis. 16(3), 524–526 (2010).
  • Briggs BJ, Atkinson B, Czechowski DM et al. Tick-borne encephalitis virus, Kyrgyzstan. Emerging Infect. Dis. 17(5), 876–879 (2011).
  • Suess J. Tick-borne encephalitis in Europe and beyond the epidemiological situation as of 2007. Euro. Surveill. 13(26), 18916 (2008).
  • Demina TV, Dzhioev YP, Verkhozina MM et al. Genotyping and characterization of the geographical distribution of tick-borne encephalitis virus variants with a set of molecular probes. J. Med. Virol. 82(6), 965–976 (2010).
  • Kunze U. 15th ISW-TBE Newsletter. ISW TBE Working Group (2011).
  • Donoso Mantke O, Schädler R, Niedrig M. A survey on cases of tick-borne encephalitis in European countries. Euro Surveill. 13(17), pii: 18848 (2008).
  • Onischenko GG, Fedorov YM, Paksina ND. Surveillance of tick-borne encephalitis and activity for its prophylactic in Russian Federation. Russian. Vopr. Virusol. 52, 8–10 (2007).
  • Han X, Juceviciene A, Uzcategui NY et al. Molecular epidemiology of tick-borne encephalitis virus in Ixodes ricinus ticks in Lithuania. J. Med. Virol. 77(2), 249–256 (2005).
  • Casati S, Gern L, Piffaretti JC. Diversity of the population of Tick-borne encephalitis virus infecting Ixodes ricinus ticks in an endemic area of central Switzerland (Canton Bern). J. Gen. Virol. 87(Pt 8), 2235–2241 (2006).
  • Dobler G, Zöller G, Poponnikova T, Gniel D, Pfeffer M, Essbauer S. Tick-borne encephalitis virus in a highly endemic area in Kemerovo (Western Siberia, Russia). Int. J. Med. Microbiol. 298(Suppl. 1), 94–101 (2008).
  • Haglund M, Günther G. Tick-borne encephalitis–pathogenesis, clinical course and long-term follow-up. Vaccine 21(Suppl. 1), S11–S18 (2003).
  • Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin. Infect. Dis. 28(4), 882–890 (1999).
  • Maximova OA, Faucette LJ, Ward JM, Murphy BR, Pletnev AG. Cellular inflammatory response to flaviviruses in the central nervous system of a primate host. J. Histochem. Cytochem. 57(10), 973–989 (2009).
  • Gelpi E, Preusser M, Garzuly F, Holzmann H, Heinz FX, Budka H. Visualization of Central European tick-borne encephalitis infection in fatal human cases. J. Neuropathol. Exp. Neurol. 64(6), 506–512 (2005).
  • Gelpi E, Preusser M, Laggner U et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. J. Neurovirol. 12(4), 322–327 (2006).
  • Holub M, Klucková Z, Beran O, Aster V, Lobovská A. Lymphocyte subset numbers in cerebrospinal fluid: comparison of tick-borne encephalitis and neuroborreliosis. Acta Neurol. Scand. 106(5), 302–308 (2002).
  • Atrasheuskaya AV, Fredeking TM, Ignatyev GM. Changes in immune parameters and their correction in human cases of tick-borne encephalitis. Clin. Exp. Immunol. 131(1), 148–154 (2003).
  • Toporkova MG, Aleshin SE, Ozherelkov SV, Nadezhdina MV, Stephenson JR, Timofeev AV. Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome. Clin. Exp. Immunol. 152(3), 517–521 (2008).
  • Kerbo N, Donchenko I, Kutsar K, Vasilenko V. Tickborne encephalitis outbreak in Estonia linked to raw goat milk, May–June 2005. Euro Surveill. 10(6), E050623.2 (2005).
  • Cizman M, Rakar R, Zakotnik B, Pokorn M, Arnez M. Severe forms of tick-borne encephalitis in children. Wien. Klin. Wochenschr. 111(12), 484–487 (1999).
  • Schmolck H, Maritz E, Kletzin I, Korinthenberg R. Neurologic, neuropsychologic, and electroencephalographic findings after European tick-borne encephalitis in children. J. Child Neurol. 20(6), 500–508 (2005).
  • Zenz W, Pansi H, Zoehrer B et al. Tick-borne encephalitis in children in Styria and Slovenia between 1980 and 2003. Pediatr. Infect. Dis. J. 24(10), 892–896 (2005).
  • Jones N, Sperl W, Koch J, Holzmann H, Radauer W. Tick-borne encephalitis in a 17-day-old newborn resulting in severe neurologic impairment. Pediatr. Infect. Dis. J. 26(2), 185–186 (2007).
  • Laursen K, Knudsen JD. Tick-borne encephalitis: a retrospective study of clinical cases in Bornholm, Denmark. Scand. J. Infect. Dis. 35(5), 354–357 (2003).
  • Mandl CW. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res. 111(2), 161–174 (2005).
  • Bröker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment. Vaccine 26(7), 863–868 (2008).
  • Arras C, Fescharek R, Gregersen JP. Do specific hyperimmunoglobulins aggravate clinical course of tick-borne encephalitis? Lancet 347(9011), 1331 (1996).
  • Bröker M, Schöndorf I. Are tick-borne encephalitis vaccines interchangeable? Expert Rev. Vaccines 5(4), 461–466 (2006).
  • Pen’evskaia NA, Rudakov NV. [Efficiency of use of immunoglobulin preparations for the postexposure prevention of tick-borne encephalitis in Russia (a review of semi-centennial experience)]. Med. Parazitol. (Mosk.) (1), 53–59 (2010).
  • Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine 21(Suppl. 1), S36–S40 (2003).
  • Kaiser R, Holzmann H. Laboratory findings in tick-borne encephalitis – correlation with clinical outcome. Infection 28(2), 78–84 (2000).
  • Klockmann U, Krivanec K, Stephenson JR, Hilfenhaus J. Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine. Vaccine 9(3), 210–212 (1991).
  • Holzmann H, Kundi M, Stiasny K et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J. Med. Virol. 48(1), 102–107 (1996).
  • Pierson TC, Sánchez MD, Puffer BA et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346(1), 53–65 (2006).
  • Loew-Baselli A, Poellabauer EM, Pavlova BG et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 29(43), 7307–7319 (2011).
  • Girgsdies OE, Rosenkranz G. Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study. Vaccine 14(15), 1421–1428 (1996).
  • Zent O, Hennig R. Post-marketing surveillance of immediate allergic reactions: polygeline-based versus polygeline-free pediatric TBE vaccine. Vaccine 23(5), 579–584 (2004).
  • Zent O, Bröker M. Tick-borne encephalitis vaccines: past and present. Expert Rev. Vaccines 4(5), 747–755 (2005).
  • Vorob’eva MS, Rasshchepkina MN, Ladyzhenskaia IP. [Vaccines, immunoglobulins, and test systems for the prevention and diagnosis of tick-borne encephalitis]. Vopr. Virusol. 52(6), 30–36 (2007).
  • Vorob’eva MS, Rasshchepkina MN, Ladyzhenskaia IP, Gorbunov MA, Pavlova LI, Bektimirov TA. [Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the ‘Immuno’ firm]. Vopr. Virusol. 41(5), 221–224 (1996).
  • Eidgenössische Kommission für Impffragen. Swiss Vaccination Schedule 2008. Guidelines and Recommendations (S VIII). Federal Office of Public Health, Bern, Switzerland (2008).
  • Zent O, Hennig R, Banzhoff A, Bröker M. Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers. J. Travel Med. 12(2), 85–93 (2005).
  • Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25(8), 1470–1475 (2007).
  • Wittermann C, Schöndorf I, Gniel D. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine 27(10), 1661–1666 (2009).
  • Rendi-Wagner P. Advances in vaccination against tick-borne encephalitis. Expert Rev. Vaccines 7(5), 589–596 (2008).
  • Zent O, Jilg W, Plentz A et al. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 21(32), 4655–4660 (2003).
  • Beran J, Douda P, Gniel D, Zent O. Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule. Int. J. Med. Microbiol. 293(Suppl. 37), 130–133 (2004).
  • Rendi-Wagner P, Kundi M, Zent O et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 23(4), 427–434 (2004).
  • Rendi-Wagner P, Hoeller K, Kollaritsch H; Osterreichische Expertengruppe für Reisemedizin. [Immunization recommendations for travel in the Mediterranean area]. Wien. Klin. Wochenschr. 116(19–20), 652–660 (2004).
  • Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults. Vaccine 27(6), 853–856 (2009).
  • Schoendorf I, Schoenfeld C, Nicolay U, Zent O, Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule. Int. J. Med. Microbiol. 296(S1), 208–212 (2006).
  • Pavlova LI, Gorbunov MA, Vorob’eva MS et al. [A cultured concentrated inactivated vaccine against tick-borne encephalitis studied during the immunization of children and adolescents]. Zh. Mikrobiol. Epidemiol. Immunobiol. (6), 50–53 (1999).
  • Gorbunov MA, Noskova AV, El’shina GA et al. [Characteristics of ‘Avaxim’ hepatitis A vaccine produced by the firm ‘Pasteur Merrier’ (results of field clinical trials)]. Vopr. Virusol. 45(1), 39–42 (2000).
  • Krasilnikov IV, Mischenko IA, Sharova OI et al. Vaccine ‘EnceVir’: development in implementaiton in pracitcal use. Biopreparations 2(14), 21–24 (2004).
  • Stavitskaya IV, Shkuratova OV, Pavlova LI, Shutova NA, Sharova OI. Immunological effetiveness of EnceVir in children. Biopreparations 2(14), 34–36 (2004).
  • Leonova GN, Pavlenko EV. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine 27(21), 2899–2904 (2009).
  • Schosser R, Kaiser R, Mansmann U, Heininger U. Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4,5 years since the last TBE vaccination. Presented at: International Jena Symposium on Tick Borne Diseases. Weimar, Germany, 19–21 March 2009.
  • Baumhackl U, Franta C, Retzl J, Salomonowitz E, Eder G. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21(Suppl. 1), S56–S61 (2003).
  • Zent O, Banzhoff A, Hilbert AK, Meriste S, Sluzewski W, Wittermann Ch. Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine 21(25–26), 3584–3592 (2003).
  • Loew-Baselli A, Konior R, Pavlova BG et al .; FSME-IMMUN study group. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine 24(24), 5256–5263 (2006).
  • Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 25(27), 5097–5101 (2007).
  • Schoendorf I, Ternak G, Oroszlàn G, Nicolay U, Banzhoff A, Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum. Vaccin. 3(2), 42–47 (2007).
  • Weinzettel R, Ertl S, Zwiauer K. [FSME monitoring: monitoring of adverse events of tick-borne-encephalitis vaccines by selected paediatricians and general practitioners]. Wien. Med. Wochenschr. 157(5–6), 107–110 (2007).
  • Loew-Baselli A, Poellabauer EM, Pavlova BG et al. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years. Hum. Vaccin. 5(8), 551–556 (2009).
  • Paulke-Korinek M, Rendi-Wagner P, Kundi M, Laaber B, Wiedermann U, Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine 27(50), 7027–7030 (2009).
  • Pöllabauer EM, Fritsch S, Pavlova BG et al. Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine. Vaccine 28(29), 4558–4565 (2010).
  • Pöllabauer EM, Pavlova BG, Löw-Baselli A et al. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine 28(29), 4680–4685 (2010).
  • Ehrlich HJ, Pavlova BG, Fritsch S et al. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 22(2), 217–223 (2003).
  • Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 23(25), 3232–3235 (2005).
  • Weinberger B, Keller M, Fischer KH et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years. Vaccine 28(20), 3511–3515 (2007).
  • Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS ONE 7(3), e34145 (2012).
  • Pavlova BG, Loew-Baselli A, Fritsch S et al. Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN ‘NEW’ in children: results of post-marketing surveillance. Vaccine 21(7–8), 742–745 (2003).
  • Wittermann C, Petri E, Zent O. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children. Vaccine 27(10), 1585–1588 (2009).
  • Krasilnikov I, Mischenko IA, Sharova OI, Vorob’eva M. Development of technology of tick-borne encephalitis vaccine (strain 205). J. Med. Microbiol. 291(Suppl. 33), 173 (2002).
  • Pavlova LI, Stavitskaya IV, Gorbunov MA et al. Immunizations of children and adolescents with concentrated purified vaccines against TBE. Biopreparations 1, 24–28 (2003).
  • Romanenko VV, Esiunina MS, Kiliachina AS. [Experience in implementing the mass immunization program against tick-borne encephalitis in the Sverdlovsk Region]. Vopr. Virusol. 52(6), 22–25 (2007).
  • Borodina TN, Evtoushok GA, Tevelenok OG, Opeikina NN. Epidemiological effectiveness of vaccination against TBE in Krasnoyarsk region. Biopreparations 2(14), 30–31 (2004).
  • Il’chenko TE, Bilalova GP, Stavitskaya NX, Solanik RG, Bistritskaya LD, Krasnilikov IV. Organization of public health. Siberian J. Med. 2, 50–55 (2009).
  • Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F. Understanding and making use of human memory B cells. Immunol. Rev. 211, 303–309 (2006).
  • Andersson CR, Vene S, Insulander M, Lindquist L, Lundkvist A, Günther G. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 28(16), 2827–2831 (2010).
  • Stiasny K, Holzmann H, Heinz FX. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine 27(50), 7021–7026 (2009).
  • Holzmann H, Vorobyova MS, Ladyzhenskaya IP et al. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine 10(5), 345–349 (1992).
  • Chiba N, Osada M, Komoro K, Mizutani T, Kariwa H, Takashima I. Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization. Vaccine 17(11–12), 1532–1539 (1999).
  • Hayasaka D, Goto A, Yoshii K, Mizutani T, Kariwa H, Takashima I. Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains. Vaccine 19(32), 4774–4779 (2001).
  • Leonova GN, Ternovoi VA, Pavlenko EV, Maistrovskaya OS, Protopopova EV, Loktev VB. Evaluation of vaccine Encepur adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis virus. Vaccine 25(5), 895–901 (2007).
  • Fritz R, Orlinger KK, Hofmeister Y et al. Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine 30(6), 1165–1169 (2012).
  • Orlinger KK, Hofmeister Y, Fritz R et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J. Infect. Dis. 203(11), 1556–1564 (2011).
  • Mansfield KL, Horton DL, Johnson N et al. Flavivirus-induced antibody cross-reactivity. J. Gen. Virol. 92(Pt 12), 2821–2829 (2011).
  • Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev. Vaccines 11(2), 177–187 (2012).
  • Ferenczi E, Bán E, Abrahám A et al. Severe tick-borne encephalitis in a patient previously infected by West Nile virus. Scand. J. Infect. Dis. 40(9), 759–761 (2008).
  • Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151–6156 (2008).
  • Al-Safi ZA, Shavell VI, Gonik B. Vaccination in pregnancy. Womens Health (Lond. Engl.) 7(1), 109–119 (2011).
  • Wolf HM, Pum M, Jáger R, István L, Mannhalter JW, Eibl MM. Cellular and humoral immune responses in haemophiliacs after vaccination against tick-borne encephalitis. Br. J. Haematol. 82(2), 374–383 (1992).
  • Prelog M, Wilk C, Keller M et al. Diminished response to tick-borne encephalitis vaccination in thymectomized children. Vaccine 26(5), 595–600 (2008).
  • Hofmann H, Haschke F, Popow C, Götz M, Klabuschnigg A, Popow-Kraupp T. [Shortening of interval between first and second TBE vaccination in asthmatic children]. Wien. Klin. Wochenschr. 93(11), 358–360 (1981).
  • Zielinski CC, Stuller I, Dorner F, Pötzi P, Müller C, Eibl MM. Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer 58(8), 1648–1652 (1986).
  • Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 31(1), 45–46 (2003).
  • Fischer M, Gibney K, MacNeil A. Tickborne encephalitis. In: Traveler’s Health – Yellow Book. Oxford University Press, GA, USA (2011).
  • Kollaritsch H, Chmelík V, Dontsenko I et al. The current perspective on tick-borne encephalitis awareness and prevention in six Central and Eastern European countries: report from a meeting of experts convened to discuss TBE in their region. Vaccine 29(28), 4556–4564 (2011).
  • Kunze U; ISW TBE. Tick-borne encephalitis: new paradigms in a changing vaccination environment. Wien. Med. Wochenschr. 161(13–14), 361–364 (2011).
  • Lundkvist A, Wallensten A, Vene S, Hjertqvist M. Tick-borne encephalitis increasing in Sweden, 2011. Euro Surveill. 16(39), pii: 19981 (2011).
  • Karaban I, Vedenkov A, Yashkova S, Sebut N. Epidemiology of tick-borne encephalitis and Lyme disease in the Republic of Belarus, 1998–2007. EpiNorth, 10(2), 48–57 (2009).
  • Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm, August 2009. Euro Surveill. 14(36), pii: 19325 (2009).
  • Pavlidou V, Geroy S, Diza E, Antoniadis A, Papa A. Epidemiological study of tick-borne encephalitis virus in northern Greece. Vector Borne Zoonotic Dis. 7(4), 611–615 (2007).
  • Lu Z, Bröker M, Liang G. Tick-borne encephalitis in mainland China. Vector Borne Zoonotic Dis. 8(5), 713–720 (2008).
  • Khastantinov M, Tserennorov D, Nymadavaa P et al. Tick-borne encephalitis in Mongolia. Presented at: 14th International Congress on Infectious Diseases. Miami, FL, USA, 9–12 March 2010 (Abstract 76.005, e372).
  • Walder G, Lkhamsuren E, Shagdar A et al. Serological evidence for tick-borne encephalitis, borreliosis, and human granulocytic anaplasmosis in Mongolia. Int. J. Med. Microbiol. 296(Suppl. 40), 69–75 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.